Top p acnes Articles in Ophthalmology

Nicotinamide inhibits Propionibacterium acnes-induced IL-8 production in keratinocytes through the NF-kB and MAPK pathways
Journal of Dermatological Science, 10/06/2009

Grange PA et al. – The authors' results indicate that nicotinamide inhibits IL–8 production through the NF–kB and MAPK pathways in an in vitro keratinocytes/P. acnes model of inflammation ... Keratinocytes involved in the innate immune response may be a suitable target for treatment during the early phase of inflammation. [more...]

Propionibacterium acnes infection after shoulder arthroplasty: A diagnostic challenge
Journal of Shoulder and Elbow Surgery, 11/03/2009

Dodson CC et al. – Prosthetic joint infection secondary to P acnes is relatively rare; yet, when present, is an important cause of clinical implant failure. Successful treatment is hampered because clinical [more...]

Characterization of bacterial flora in persistent apical periodontitis lesions
Oral Microbiology and Immunology, 10/15/2009

Fujii R et al. – The microbiota of persistent apical periodontitis lesions is composed by diverse types of microorganisms with biofilm–forming capacity, including P. acnes, S. epidermidis and F. nucleatum. [more...]

Etanercept overcomes P-glycoprotein-induced drug resistance in lymphocytes of patients with intractable rheumatoid arthritis
Modern Rheumatology, 11/19/2009

Tsujimura S et al. – Etanercept is useful for overcoming P-gp-mediated treatment resistance in intractable RA patients who have to discontinue infliximab or are intolerant to MTX. p> p> Peripheral lymphocytes of 11 RA patients (3 switched from infliximab and 8 who could not be treated with MTX) were analyzed for P-gp expression by flow cytometry and for drug exclusion using radioisotope-labeled dexamethasone. p>Results Activated ... P-gp and coexpressed CD69. Incubation of these lymphocytes with dexamethasone in vitro reduced intracellular dexamethasone levels. Two-week etanercept therapy significantly reduced P-gp expression and eliminated such P-gp- and CD69-high-expressing subgroup. The reduction in P [more...]

Choosing the best treatments for acne
The Clinical Advisor, 11/03/2009

McMichael AJ et al. – Acne is a multifaceted skin disease that can have far–reaching consequences. The list of severe and devastating side effects may be short, but it is impressive. Early diagnosis and treatment are the mainstays of acne management and can ... modes available for the treatment of acne are a testament to the varied needs of acne patients. A balanced review of lesion type, patient requirements, and underlying expectations can make the difference in controlling acne vulgaris. Acne severity correlates with increased anxiety, anger ... consequences. Menstruation, pregnancy, and hyperandrogenic states can exacerbate acne. Retinoids and retinoid–analogs prevent development of the microcomedo and comprise reasonable first–line agents. A topical retinoid combined with an antibiotic (either ... cosmetic derm/acne,dermatology [more...]

A phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma
Journal of Clinical Oncology, 10/19/2009

S et al. – E + P resulted in a statistically significant doubling of median PFS, with an acceptable toxicity profile and encouraging OS. A multinational, phase III trial (SYMMETRY) of E + P compared with paclitaxel alone in metastatic melanoma has closed.p> Methods p> Randomly ... with metastatic melanoma, measurable disease, and one or fewer prior chemotherapy regimens to elesclomol 213 mg/m2 plus paclitaxel 80 mg/m2 (E + P) or to paclitaxel 80 mg/m2 alone at a 2:1 ratio Regimens were given as 1-hour intravenous infusion weekly, during 3 of every 4 weeks until ... to cross over to E + P Primary efficacy end point progression-free survival (PFS) Secondary end points response rate (RR), toxicity, and overall survival p>Results At 21 US sites, 53 patients randomly assigned to E + P, and 28 patients randomly assigned to ... progression/death Respective RRs for E + P and paclitaxel groups were 15% and 3%; median OS was 11.9 v 7.8 months Of patients on paclitaxel alone, 19 [68%] of 28 crossed over to E + P after progression Weekly E + P well tolerated [more...]

Spurious amplification of P. vivax small subunit RNA gene using the primers currently used to detect P. knowlesi
Journal of Clinical Microbiology, 10/08/2009

Imwong M et al. – The PCR primers commonly used to detect P. knowlesi infections in humans were found to cross–react stochastically with P. vivax genomic DNA. A nested ... P. knowlesi small subunit ribosomal RNA genes, was validated for specificity and for sensitivity of detection of < 10 parasite genomes. [more...]

Sirolimus-induced signaling modifications in Kaposis sarcoma with resolution in a liver transplant recipient
Clinical Transplantation, 11/18/2009

et al. – p–Akt and p–mTOR, which were decreased at two months, could not be detected after one yr of treatment. Moreover, p–p70 S6 kinase, expressed strongly in overlying epidermis initially, was suppressed completely after two months of treatment. However, p–tuberin ... suggested theoretically, was not detected through all specimens, implying not to be a significant event. Suppressed expression of VEGF, p–Akt, and p–mTOR was the major event of signaling modification through the long–term use of sirolimus. [more...]

Serum concentrations of interleukin 1î², cxcl10, and interferon-î³ in mixed cryoglobulinemia associated with hepatitis c infection
Journal of Rheumatology, 11/20/2009

vasculitis in MC+HCV patients. p> Methods p> Serum IL-1ß, IFN-?, and CXCL10 were assayed in 54 patients with MC+HCV, in 54 sex- and age-matched patients with type C chronic hepatitis without cryoglobulinemia (HCV+), and in 54 controls. p>Results MC+HCV ... 1ß and CXCL10 serum levels than controls (p < 0.01) or HCV+ patients (p < 0.01). CXCL10 was significantly increased in 14 cryoglobulinemic patients with active vasculitis (necrotizing vasculitis or vasculitic skin ulcers) compared to those without (p < 0.001); IL-1ß was increased in ... p = 0.06). No differences were observed for serum IFN-? levels. [more...]

Survivin as a prognostic marker for urothelial carcinoma of the bladder: A multicenter external validation study
Clinical Cancer Research, 11/17/2009

our accuracy for prediction of cancer recurrence and survival in pT1-3N0M0 patients by a small but statistically significant margin. p> Methods p> Study comprised 726 patients treated with radical cystectomy and bilateral pelvic lymphadenectomy Survivin staining and ... considered altered Predictive accuracy quantified using concordance index and 200-bootstrap resamples used to reduce overfit bias p>Results Survivin was independent predictor of disease recurrence and cancer-specific survival in multivariable analyses that ... P = 0.67 for disease recurrence and P = 0.27 for cancer-specific survival) In subgroup of patients with pT1-3N0M0 disease (n = 398), addition of survivin improved accuracy of standard clinicopathologic features for prediction of disease recurrence and cancer-specific survival (1.3%, P ... 0.001 and 1.2%, P < 0.001, respectively) [more...]